Likelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Non-Small Cell Lung Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Ivonescimab in Non-Small Cell Lung Cancer Drug Details:
Ivonescimab (Idafang) acts as an anti-neoplastic agent. It is formulated as injectable solution for intravenous route of administration. Idafang is indicated along with pemetrexed and carboplatin for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) gene mutations who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)Ivonescimab (AK-112) is under development for the treatment of solid tumors like renal cell carcinoma, elapsed or metastatic thymic cancer, recurrent glioblastoma, cutaneous squamous cell carcinoma, triple-negative breast cancer, metastatic melanoma, human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer), small-cell lung cancer, hepatocellular carcinoma and squamous and non-squamous non-small cell lung cancer, bile duct cancer (cholangiocarcinoma), recurrent or metastatic cervical squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma, recurrent or metastatic biliary tract cancers, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, recurrent or metastatic pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), colorectal cancer, metastatic colorectal cancer, non-small cell lung cancer, small-cell lung cancer, sarcomas and recurrent or metastatic head And neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The therapeutic candidate is a bi-specific antibody targeting programmed cell death protein 1 (PD-1) and VEGF. It is administered through intravenous and intravenous drip route. It is developed based on antibody analytical (ACE) platform.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas | |||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports